Reaction
Cutaneous Mucormycosis reporting signals
As of the last recalculation, Cutaneous Mucormycosis appears in 176 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is ATOVAQUONE (PRR 350.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Atovaquone | 21 | 350.1 | 351.0 |
| Valganciclovir Hydrochloride Powder, | 26 | 295.6 | 296.2 |
| Basiliximab | 21 | 239.6 | 240.1 |
| Valganciclovir | 27 | 199.9 | 200.2 |
| Valganciclovir Hydrochloride | 27 | 199.9 | 200.2 |
| Phytonadione | 11 | 163.5 | 163.7 |
| Remdesivir | 15 | 145.4 | 145.6 |
| Amphotericin B | 13 | 132.4 | 132.6 |
| Posaconazole Delayed-Release | 11 | 126.3 | 126.4 |
| Cefepime | 12 | 106.2 | 106.3 |
| Cefepime Hydrochloride | 12 | 94.5 | 94.5 |
| Posaconazole | 11 | 85.3 | 85.4 |
| Linezolid | 16 | 69.8 | 69.9 |
| Norepinephrine | 5 | 56.9 | 56.9 |